News and press releases
Stay up to date with the Association’s news and events.
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809b0acaf27b0a4de4c33_resources-hero_cell1.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809af6100c642491b1144_resources-hero_cell2.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809b0c9a071f3e1315c44_resources-hero_cell3.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809aff7e7c55068ea25b5_resources-hero_cell4.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809b0c077d95e001f56d8_resources-hero_cell5.webp)
![](https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/63c809b0a95ec247802ff9ad_resources-hero_cell6.webp)
Quick links
Press releases
PPTA statements
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mar 10, 2021
New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs
The International Plasma and Fractionation Association and the Plasma Protein Therapeutics Association are pleased with the recent publication by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) "CHMP Position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour," as such a position was highly needed, especially regarding men-having-sex-with-men (MSM).
All
PPTA statements
Mar 10, 2021
New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs
The International Plasma and Fractionation Association and the Plasma Protein Therapeutics Association are pleased with the recent publication by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) "CHMP Position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour," as such a position was highly needed, especially regarding men-having-sex-with-men (MSM).
All
PPTA statements
Feb 25, 2021
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients
February 25, 2021 (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency.
All
Press releases
Feb 25, 2021
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients
February 25, 2021 (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency.
All
Press releases
Feb 10, 2021
Human Plasma Donations Remain Important During COVID-19 Pandemic
In a recent communication, the U.S. Food and Drug Administration (FDA) limits the collection and use of COVID-19 convalescent plasma authorized under Emergency Use Authorization for the treatment of hospitalized patients with COVID-19.1 It is important to note, however, that this development does not mean that the need for plasma donations has diminished.
All
PPTA statements
Feb 10, 2021
Human Plasma Donations Remain Important During COVID-19 Pandemic
In a recent communication, the U.S. Food and Drug Administration (FDA) limits the collection and use of COVID-19 convalescent plasma authorized under Emergency Use Authorization for the treatment of hospitalized patients with COVID-19.1 It is important to note, however, that this development does not mean that the need for plasma donations has diminished.
All
PPTA statements
Jan 25, 2021
PPTA Statement on Immunoglobulin Use to Meet Clinical Need
A recent publication1 explores possible reasons for the increased use of immunoglobulins (IG) and suggests growing clinical need can be met by restricting patient access to IG while denying the need to collect more plasma in Europe.
All
PPTA statements
Jan 25, 2021
PPTA Statement on Immunoglobulin Use to Meet Clinical Need
A recent publication1 explores possible reasons for the increased use of immunoglobulins (IG) and suggests growing clinical need can be met by restricting patient access to IG while denying the need to collect more plasma in Europe.
All
PPTA statements
No results found